In view of the safety of roxadustat in the treatment of renal anemia

relevant domestic and foreign literature were searched and analyzed from the aspects of mechanism of action

pharmacokinetics

pharmacodynamics and drug safety research at home and abroad. It is found that while increasing hemoglobin

roxadustat may cause adverse drug reactions such as cardiovascular events

vascular access thrombosis

deep vein thrombosis

seizures and severe infections

and there is a tendency of higher safety risk compared with placebo or control drugs. It is suggested that roxadustat can effectively improve the symptoms of renal anemia in patients

yet the safety of roxadustat should be paid more attention.